Stock VVY VIVORYON THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Market Closed - Euronext Amsterdam
Other stock markets
 16:35:10 10/05/2024 BST 		5-day change 1st Jan Change
0.795 EUR -1.85% Intraday chart for Vivoryon Therapeutics N.V. +4.47% -90.23%
04-24 Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
03-15 Vivoryon Therapeutics N.V Announces Resignation of Board of Directors CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease
CI
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
CI
Vivoryon Rises 7% on EUR25 Million Capital Raise
MT
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Vivoryon Therapeutics Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (News with Additional Features)
CI
Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2B Study of Varoglutamstat in AD
CI
Vivoryon Therapeutics N.V. Announces the Appointment of Dr. Claudia Riedl and Samir Shah to its Non-Executive Board of Directors
CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Vivoryon Therapeutics Wins China Nod to Start Clinical Trial of Alzheimer's Therapy
MT
Simcere Pharma Wins Clinical Trial Approval in China for Alzheimer's Disease Treatment
MT
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease
CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Vivoryon Therapeutics N : Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease
PU
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease
EQ
Vivoryon Therapeutics N.V Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease (News with Additional Features)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VVY Stock
  4. News Vivoryon Therapeutics N.V.
  5. Highlights